派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02565 派格生物医药-B

休市中 11-13 16:08:17

3.250

-0.125

-3.70%

最高3.530	最低3.250	成交量1,840万
今开3.415	昨收3.375	日振幅8.30%
总市值13.59亿	流通市值13.42亿	总股本4.18亿
成交额6,219万	换手率4.46%	流通股本4.13亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物医药-B","latestPrice":3.25,"timestamp":1794557297007,"preClose":3.375,"halted":0,"volume":18404000,"delay":0,"changeRate":-0.037037037037037035,"floatShares":413000000,"shares":418000000,"eps":-0.55,"marketStatus":"休市中","change":-0.125,"latestTime":"11-13 16:08:17","open":3.415,"high":3.53,"low":3.25,"amount":62192457,"amplitude":0.082963,"askPrice":3.25,"askSize":41050,"bidPrice":3.245,"bidSize":14300,"shortable":3,"etf":0,"ttmEps":-0.912,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":7,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":3.375,"openAndCloseTimeList":[[1794533400000,1794542400000],[1794546000000,1794556800000]],"volumeRatio":0.7275941792508808,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02565","defaultTab":"news","newsList":[{"id":"1123618678","title":"派格生物医药-B（02565）11月26日召开临时股东大会　拟解聘毕马威并改聘容诚","url":"https://stock-news.laohu8.com/highlight/detail?id=1123618678","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123618678?lang=zh_cn&edition=full","pubTime":"2026-11-11 16:40","pubTimestamp":1794386440,"startTime":"0","endTime":"0","summary":"委任代表表格须于11月25日10:00前递交香港中央证券登记；投票结果将按上市规则公布于上述网站。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123815618","title":"派格生物医药-B配售2681.30万股H股，募集约8003.68万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1123815618","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123815618?lang=zh_cn&edition=full","pubTime":"2026-11-10 18:15","pubTimestamp":1794305750,"startTime":"0","endTime":"0","summary":"派格生物医药-B于2026年11月10日发布公告，根据一般授权完成配售新H股，共计发行26,813,000股，配售价为每股2.985港元，合计募集资金约8003.68万港元。\n此次发行股份数量占发行前公司已发行股本386,002,390股的约6.9463%。发行完成后，公司已发行股本增至412,815,390股，库藏股数为0。\n公司同时确认，其已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由联席公司秘书黄一峰签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"派格生物医药-B配售2681.30万股H股，募集约8003.68万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682639305","title":"派格生物医药-B(02565.HK)11月10日完成配售2681.3万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2682639305","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682639305?lang=zh_cn&edition=full","pubTime":"2026-11-10 18:13","pubTimestamp":1794305635,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169407937","title":"派格生物医药-B（02565）完成新H股配售 募资约8,004万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169407937","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169407937?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:36","pubTimestamp":1794303370,"startTime":"0","endTime":"0","summary":"2026年11月10日，派格生物医药-B公告，公司已根据一般授权完成新H股配售。配售协议所列全部条件已获达成，配售于同日完成。本次配售价格为每股2.985港元，独家配售代理向不少于6名承配人发行26,813,000股新H股，占配售完成后经扩大H股约6.50%、占公司总股本约6.42%。配售所得款项总额约8,004万港元，扣除相关成本及开支后，所得款项净额约7,716万港元。配售完成后，公司已发行股份由391,091,532股增至417,904,532股，其中H股由386,002,390股增至412,815,390股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682398327","title":"派格生物医药-B(02565)完成发行合共2681.3万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2682398327","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682398327?lang=zh_cn&edition=full","pubTime":"2026-11-10 17:34","pubTimestamp":1794303296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B(02565)发布公告，配售协议的所有条件已获达成，配售已于2026年11月10日完成。根据配售协议的条款及条件，独家配售代理已以每股配售股份2.985港元的价格向不少于六名承配人配售合共2681.3万股配售股份，相当于紧随配售完成后，经配发及发行配售股份扩大的H股的约6.50%及股份总数的约6.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1521134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161726","BK4581","BK4585","XBI","399441","BK1161","BK4588","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136241909","title":"派格生物医药-B（02565）宣布取消11月12日临时股东大会并改期至11月26日","url":"https://stock-news.laohu8.com/highlight/detail?id=1136241909","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136241909?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:11","pubTimestamp":1793974287,"startTime":"0","endTime":"0","summary":"派格生物医药-B11月6日公告，为确保公司配售及发行新H股事项顺利完成，公司董事会决议取消原定于2026年11月12日上午10时举行的2026年第一次临时股东大会。随之，原计划自2026年11月9日至2026年11月12日的H股股份过户登记暂停期亦同步取消。公司确认，2026年11月20日（星期五）为重新召开的临时股东大会的股权登记日，当日在H股证券登记处股东名册上登记的H股股东有权出席并投票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681583588","title":"港股异动 | 派格生物医药-B(02565.HK)尾盘涨超10% 维培那肽有望进入医保 公司融资保障下一轮产品研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2681583588","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681583588?lang=zh_cn&edition=full","pubTime":"2026-11-06 15:41","pubTimestamp":1793950916,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171179888","title":"派格生物医药-B10月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1171179888","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171179888?lang=zh_cn&edition=full","pubTime":"2026-11-04 16:42","pubTimestamp":1793781754,"startTime":"0","endTime":"0","summary":"派格生物医药(杭州)股份有限公司于2026年11月4日发布截至2026年10月31日的股份变动月报表。报告显示，本期各类股本结构维持不变，且公司确认符合香港联交所上市规则的公众持股量要求。根据公告，派格生物医药-B的注册股本总额约为人民币3.91亿元，其中H股股本为人民币3.86亿元，非上市股份股本约为人民币508.91万元。截至10月末，H股及非上市股份数量均未出现增减，亦未发生新增发行、股份回购或注销情形。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680442711","title":"派格生物(02565)：逆风完成融资，商业化与创新管线价值正在浮出水面","url":"https://stock-news.laohu8.com/highlight/detail?id=2680442711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680442711?lang=zh_cn&edition=full","pubTime":"2026-11-03 13:55","pubTimestamp":1793685328,"startTime":"0","endTime":"0","summary":"在港股创新药融资环境持续承压之际，派格生物医药交出了一份值得正面评价的资本市场答卷。权益金不等同于产品销售收入，但足以说明派格的研发资产已开始通过商业交易实现价值。派格本次预计净募集约7,716万港元，其中约60%用于下一代管线研发、约20%用于偿还贷款及强化资本结构、约20%用于营运资金及一般公司用途。派格的产品获批、商业化合作和逆风融资是已经发生的事实;下一阶段需要兑现的是收入增长、研发节点与经营效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680791587","title":"派格生物医药-B(02565.HK)拟折让19.00%配售2681.3万股 净筹约7716万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680791587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680791587?lang=zh_cn&edition=full","pubTime":"2026-11-03 06:58","pubTimestamp":1793660301,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680791580","title":"派格生物医药-B(02565)拟折让19.00%配售2681.3万股 净筹约7716万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680791580","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680791580?lang=zh_cn&edition=full","pubTime":"2026-11-03 06:58","pubTimestamp":1793660301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布公告，于2026年11月2日，公司与独家配售代理订立配售协议，据此，公司已有条件同意透过独家配售代理按尽力基准以每股配售股份2.985港元的价格向不少于六名承配人配售合共2681.3万股配售股份，该等配售股份将由公司根据一般授权按配售协议所载条款及条件发行。假设所有配售股份获悉数配售，配售的估计所得款项总额及所得款项净额将分别为约8004万港元及约7716万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02565","BK4588","BK1161","BK4581","161726","BK4585","XBI","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680799080","title":"派格生物医药-B：拟配售2681.30万股新H股，每股配售价2.99港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680799080","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680799080?lang=zh_cn&edition=full","pubTime":"2026-11-03 06:37","pubTimestamp":1793659034,"startTime":"0","endTime":"0","summary":"南财智讯11月3日电，派格生物医药-B（02565.HK）公告，于2026年11月2日，公司与独家配售代理麦格理资本订立配售协议，拟按尽力基准向不少于六名承配人配售合共2681.30万股新H股，配售价为每股2.985港元。配售股份占公告日期已发行H股约6.95%及已发行股份总数约6.86%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611033919214045.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611033919214045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4581","BK4585","XBI","BK4588","02565","EWH","161726","BK1161","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124327051","title":"派格生物医药-B（02565）拟折让19%配售2,681.3万股H股 最高募资约8.00亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124327051","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124327051?lang=zh_cn&edition=full","pubTime":"2026-11-03 06:10","pubTimestamp":1793657441,"startTime":"0","endTime":"0","summary":"11月3日，派格生物医药-B公布，已于2026年11月2日与麦格理资本股份有限公司签订配售协议，拟通过其独家配售代理以每股2.985港元向不少于六名承配人配售新H股共2,681.3万股。– 预计配售所得款项总额约8.00亿港元，扣除相关费用后，净募资约7.72亿港元，对应每股净价约2.878港元。– 配售完成后，已发行股份将增至4.18亿股，其中H股增至4.13亿股。– 2025年12月，公司曾以每股58.41港元向不少于六名承配人配售513.6万股H股，募集净额约2.96亿港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679251744","title":"港股异动 | 派格生物医药-B(02565)最高涨超30% 维培那肽医保准入预期升温 创新药管线持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2679251744","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679251744?lang=zh_cn&edition=full","pubTime":"2026-10-30 09:40","pubTimestamp":1793324457,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B今早最高涨超30%，报5港元，现成交额约8051.63万港元。消息面上，派格生物核心产品维培那肽注射液（派达康）已获国家药监局批准上市。值得关注的是，维培那肽已进入2026年国家医保目录调整相关程序。随着新一轮国家医保目录公布临近，产品医保准入进展受到市场关注。若成功纳入医保，有望进一步提升患者用药可及性，为后续商业化放量创造条件。此外，公司持续推进下一代代谢疾病创新药研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06978","VXUS","LNGR","159992","161726","399441","IBBQ","MEDX","XBI","BK4588","BK4581","KCAI","02565","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679251741","title":"港股异动 | 派格生物医药-B(02565.HK)最高涨超30% 维培那肽医保准入预期升温 创新药管线持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2679251741","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679251741?lang=zh_cn&edition=full","pubTime":"2026-10-30 09:40","pubTimestamp":1793324457,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1161","02565","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156503309","title":"派格生物医药-B（02565）将于11月12日召开临时股东大会审议更换核数师及调整募资用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1156503309","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156503309?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:06","pubTimestamp":1792757172,"startTime":"0","endTime":"0","summary":"派格生物医药-B公告，公司拟于2026年11月12日（周四）10:00在浙江省杭州市拱墅区绍兴路520号A座6楼举行2026年第一次临时股东大会。\\n\\n公司将按香港联交所上市规则以投票方式表决。H股过户登记将于11月9日至11月12日暂停，11月6日16:30前完成过户的股东可于11月12日名列股东名册；委任代表表格须在11月11日10:00前送达香港中央证券登记有限公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197205567","title":"派格生物医药-B 9月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1197205567","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197205567?lang=zh_cn&edition=full","pubTime":"2026-10-07 22:35","pubTimestamp":1791383747,"startTime":"0","endTime":"0","summary":"派格生物医药（杭州）股份有限公司于2026年10月7日发布截至2026年9月30日的股份变动月报。报告期内，公司注册股本维持在人民币391,091,532元，已发行股本无新增发行或购回注销行为，股本结构稳定。公司确认满足香港联交所要求的公众持股量条件。公司表示，将继续遵守香港联交所《上市规则》及其他适用法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175344669","title":"派格生物医药-B 2026年中期财报：营收0元，经调整净利润-1.82亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175344669","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175344669?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:59","pubTimestamp":1790153947,"startTime":"0","endTime":"0","summary":"本季度信息\n根据派格生物医药-B（02565）披露的2026年中期报告显示，截至2026年6月30日止六个月，营收0元，较上年同期保持不变。经调整净亏损为1.82亿元，上年同期该项数据为0.51亿元，亏损额同比扩大约256%。\n财报显示，研发投入为1.10亿元，上年同期为0.26亿元；销售及营销费用为0.21亿元，上年同期为0.05亿元；管理开支为0.72亿元，上年同期为0.61亿元。经营活动所用净现金流为1.55亿元，较上年同期的0.78亿元有明显增长。\n由于核心产品进入商业化推广阶段，销售和营销费用大幅增加。此外，研发投入维持高位，进一步推动了经调整净亏损的扩大。\n","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"派格生物医药-B 2026年中期财报：营收0元，经调整净利润-1.82亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103921140","title":"派格生物医药-B（02565）拟将约0.96亿元 IPO 余款转投 PB-119 商业化及上市后研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1103921140","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103921140?lang=zh_cn&edition=full","pubTime":"2026-09-18 22:31","pubTimestamp":1789741868,"startTime":"0","endTime":"0","summary":"财联社讯，2026年9月18日，派格生物医药-B 公告称，董事会已决议调整部分首次公开发售所得款项的用途，将原规划用于 PB-119 若干临床研发项目的未动用资金约人民币95.5百万元全部转投 PB-119 的商业化及上市后研究。该调整尚待股东于临时股东大会审议通过。公司于2025年5月上市，实际募集资金净额约人民币212.6百万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668992112","title":"派格生物医药-B(02565)建议委任容诚香港为新任核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2668992112","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668992112?lang=zh_cn&edition=full","pubTime":"2026-09-18 22:26","pubTimestamp":1789741586,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B(02565)发布公告，由于公司与毕马威会计师事务所(毕马威)未能就截至2026年12月31日止年度的核数费用达成共识，经董事会审计委员会推荐，公司建议解聘毕马威作为公司截至2026年12月31日止年度的核数师并委任容诚(香港)会计师事务所有限公司(容诚香港)为公司截至2026年12月31日止年度的新任核数师，以填补建议解聘后产生的临时空缺，并任职直至公司下届股东周年大会结束为止。建议更换核数师须待(其中包括)公司将召开的临时股东大会通过相关决议案后，方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02565","399441","BK4585","XBI","161726","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pegbio.com","stockEarnings":[{"period":"1week","weight":-0.0483},{"period":"1month","weight":-0.2554},{"period":"3month","weight":-0.4783},{"period":"6month","weight":-0.7096},{"period":"1year","weight":-0.9424},{"period":"ytd","weight":-0.9529}],"compareEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":-0.0278},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0896},{"period":"1year","weight":-0.1269},{"period":"ytd","weight":-0.0778}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"派格生物医药（杭州）股份有限公司是一家主要从事研究及开发慢性病创新疗法的中国公司。该公司的主要产品PB-119是自主开发、接近商业化阶段的长效胰高血糖素样肽1（GLP-1，一种降低血糖水平的肽类激素）受体激动剂。该公司的候选产品包括PB-718、PB-1902、PB-722、PB-2301和PB-2309。该公司的产品主要用于治疗2型糖尿病（T2DM）、肥胖症、非酒精性脂肪性肝炎（NASH）、阿片类药物引起的便秘（OIC，使用阿片类药物引起的胃肠道疾病）及先天性高胰岛素血症（一种罕见的内分泌疾病，患者持续出现低血糖症）等常见慢病及代谢疾病。","exchange":"SEHK","name":"派格生物医药-B","nameEN":"PEGBIO CO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派格生物医药-B,02565,派格生物医药-B股票,派格生物医药-B股票老虎,派格生物医药-B股票老虎国际,派格生物医药-B行情,派格生物医药-B股票行情,派格生物医药-B股价,派格生物医药-B股市,派格生物医药-B股票价格,派格生物医药-B股票交易,派格生物医药-B股票购买,派格生物医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}